Antidiabetic Activity of Afobazole in Wistar Rats.

Abstract

Using the streptozotocin model of type 2 diabetes mellitus in Wistar rats, we compared antidiabetic activity of anxiolytic Afobazole with that of metformin. Afobazole in a dose of 10 mg/kg reduced streptozotocin-induced hyperglycemia and polyphagia and prevented accumulation of malonic dialdehyde, being not inferior to metformin in a dose of 300 mg/kg, and was even more effective than metformin in body weight recovery, elimination of polydipsia, and preservation of these effects after treatment withdrawal.

• Authors: R U Ostrovskaya, S V Ivanov, M V Voronin, I V Ozerova, N N Zolotov, S B Seredenin
• Journal: Bulletin of experimental biology and medicine (Bull Exp Biol Med) Vol. 165 Issue 5 Pg. 649-652 (Sep 2018) ISSN: 1573-8221 [Electronic] United States
• PMID: 30225697 (Publication Type: Journal Article)

Chemical References

• 2-((2-morpholino)ethylthio)-5-ethoxybenzimidazole
• Anti-Anxiety Agents
• Benzimidazoles
• Blood Glucose
• Hypoglycemic Agents
• Morpholines
• Streptozocin
• Metformin

Topics

• Animals
• Anti-Anxiety Agents (pharmacology)
• Benzimidazoles (pharmacology)
• Blood Glucose (drug effects)
• Body Weight (drug effects)
• Diabetes Mellitus, Experimental (chemically induced, drug therapy, metabolism, pathology)
• Drug Repositioning
• Hyperglycemia (chemically induced, drug therapy, metabolism, pathology)
• Hyperphagia (prevention & control)
• Hypoglycemic Agents (pharmacology)
• Male
• Metformin (pharmacology)
• Morpholines (pharmacology)
• Rats
• Rats, Wistar
• Streptozocin